Hormone therapy may not protect against Alzheimer’s disease

156

The latest study on hormone therapy and Alzheimer’s disease shows no relationship between taking the drugs and developing the disease years later. Some previous studies have shown that hormone therapy may increase the risk of the disease, while others have shown that it may reduce the risk. The new study was published online in Neurology.

“While women still need to talk to their doctors about the risks and benefits of taking hormone therapy during menopause, this study did not provide strong evidence that taking hormone therapy can protect women from Alzheimer’s disease,” says study author Bushra Imtiaz of the University of Eastern Finland in Kuopio, Finland.

For the study, all women aged 47 to 56 living in Kuopio Province received questionnaires in the mail every five years from 1989 until 2009. Information on hormone therapy use was provided by women and also available from a Finnish registry starting in 1995. Diagnoses of Alzheimer’s disease were based on a registry.

Of the 8,195 women who were followed for the full 20-year study, 4,401 reported using hormone therapy. A total of 227 women developed Alzheimer’s disease during the study.

Use of hormone therapy after menopause was not associated with Alzheimer’s disease risk. This was true when researchers looked at both the information the women reported themselves and the information from the registry.

When researchers looked only at the women who reported that they had used hormone therapy for more than 10 years, they found a reduced risk of Alzheimer’s disease compared to women who did not use hormone therapy. However, the result was not as strong when researchers looked at hormone use and any type of dementia. When researchers looked at women who used hormone therapy for more than 10 years based on the registry data, they did not find any reduced risk of Alzheimer’s disease. Imtiaz said one explanation for the different results could be the different time period for self-reported data and registry data.

Imtiaz said limitations of the study are that some information was self-reported by participants, who may not recall information accurately and that researchers could not control the results for people who had a genetic predisposition to Alzheimer’s disease.